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Abstract
Background We need new biomarkers that can predict car-
diovascular disease to improve both diagnosis and thera-
peutic strategies. The CIRCULATING CELLS study was
designed to study the role of several cellular mediators
of atherosclerosis as biomarkers of coronary artery disease
(CAD). An objective and reproducible method for the quan-
tification of CAD extension is required to establish relation-
ships with these potential biomarkers. We sought to analyse
the correlation of the SYNTAX score with known CAD risk
factors to test it as a valid marker of CAD extension.
Methods and results A subgroup of 279 patients (67.4%
males) were included in our analysis. Main exclusion cri-
teria were a history of previous percutaneous coronary in-
tervention or surgical revascularisation that prevent an ac-
curate assessment of the SS. Diabetes mellitus, smoking,
renal insufficiency, body mass index and a history of CAD
and myocardial infarction were all positively and strongly
associated with a higher SYNTAX score after adjustment
for the non-modifiable biological factors (age and sex). In
the multivariate model, age and male sex, along with smok-
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ing and renal insufficiency, remain statistical significantly
associated with the SYNTAX score.
Conclusion In a selected cohort of revascularisation-naive
patients with CAD undergoing coronary angiography, non-
modifiable cardiovascular risk factors such as advanced age,
male sex, as well as smoking and renal failure were inde-
pendently associated with CAD complexity assessed by the
SYNTAX score. The SYNTAX score may be a valid marker
of CAD extension to establish relationships with potential
novel biomarkers of coronary atherosclerosis.
Keywords Coronary artery disease · Coronary
angiography · Risk assessment · Risk factors
Introduction
The search for new biomarkers that predict cardiovascu-
lar disease has become a priority in the need to improve
early diagnosis and establish individual treatment strategies.
The CIRCULATING CELLS study was designed to study
a broad spectrum of features associated with circulating
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hematopoietic cellular subsets as biomarkers of coronary
artery disease (CAD) and atherosclerosis [1].
In order to analyse potential relationships of novel mark-
ers with the extension of CAD, reproducible and objec-
tive methods for coronary atherosclerosis quantification are
needed. The Synergy between Percutaneous Coronary Inter-
vention with Taxus and Cardiac Surgery (SYNTAX) score
(SS) has emerged as a tool to objectively quantify CAD
complexity from an anatomical point of view, offering prog-
nostic information and guidance concerning the appropriate
coronary revascularisation method [2]. Since its introduc-
tion, SS has also been used as a method to provide objective
and reproducible anatomical information about the extent
of CAD [3].
Classical determinants of cardiovascular disease such as
age, male gender, hypertension, dyslipidaemia, diabetes and
smoking have been linked to more extensive forms of CAD
[4]. A more complex disease pattern, reflected by a higher
SS, is therefore expected in patients with a higher risk pro-
file. The evidence associating SS with a higher risk profile,
is however still scarce [5].
We sought to analyse the correlation of SS, as a marker
of CAD extension, with traditional and other known risk
factors related with the development of coronary atheroscle-
rosis in participants of the CIRCULATING CELLS study
[1].
Methods
Study cohort
The cohort consists of 279 subjects, representing a sub-
group of the CIRCULATING CELLS study population. The
CIRCULATING CELLS study was a multicentre, prospec-
tive study conducted from March 2009 to September 2011
in four medical centres in the Netherlands [1]. The total
number of patients enrolled was 714. For the needs of our
analysis, patients with previous history of coronary inter-
vention (percutaneous coronary intervention, or coronary
artery bypass grafting) were not included.
According to the study protocol, described in detail
elsewhere [1], patients admitted with chest pain and a pro-
visional diagnosis of stable angina, unstable angina or non-
ST-segment elevation myocardial infarction (NSTEMI)
were considered eligible for inclusion. Patients present-
ing with ST-segment elevation myocardial infarction were
excluded. All patients underwent a diagnostic coronary
angiography. Blood samples were collected at inclusion
and stored for further analysis. We entered the obtained
data into a centralised database.
The study was approved by the ethics committee at
each participating centre and conforms to the declaration
of Helsinki. All patients provided written informed consent
at inclusion.
Assessment of cardiovascular risk determinants
The CIRCULATING CELLS database was used to obtain
information about the prevalence of cardiovascular risk de-
terminants. Age, sex, hypertension, diabetes, dyslipidaemia,
smoking habits, family history of premature coronary artery
disease, renal insufficiency, prior history of myocardial in-
farction and prior peripheral and cerebrovascular disease
data were collected. Body mass index (BMI) was calcu-
lated and included in the analysis.
Hypertension was considered present when systolic
blood pressure was ≥140 mm Hg and/or diastolic blood
pressure ≥90 mm Hg or in the event of chronic use of blood
pressure-lowering agents. Diabetes was considered present
if the subject was treated with insulin or oral hypogly-
caemic drugs or if fasting serum glucose was ≥7.0 mmol/l
or serum glucose ≥11.1 mmol/l at admission. Dyslipi-
daemia was defined as total cholesterol >5.0 mmol/l, low-
density lipoprotein (LDL) cholesterol >3.2 mmol/l or the
use of lipid-lowering drugs. Patients who had been smok-
ing regularly within 12 months prior to the inclusion were
considered smokers.
Renal insufficiency was considered present if previously
reported or serum creatinine value measured at inclu-
sion >150μmol/l. Cerebrovascular disease was considered
present if previous history of transient ischaemic attack,
cerebral infarction, cerebral ischaemia or amaurosis fugax
had been reported. Peripheral artery disease was defined
as a symptomatic and documented obstruction of distal
arteries of the leg or interventions, or history of abdominal
or infrarenal aortic aneurysm.
SS measurements
All coronary angiograms obtained at inclusion were evalu-
ated at the Leiden University Medical Centre by two expe-
rienced interventional cardiologists. SS was calculated with
the use of the online calculator and following the definitions
of the SYNTAX study [2] (www.syntaxscore.com). In cases
of disagreement, the opinion of a third analyst was obtained
and the final decision was made by consensus.
Statistical analysis
Continuous variables are expressed as mean ± standard de-
viation (SD) and categorical variables are expressed as per-
centages. Using the general linear model, univariate analy-
sis was performed to identify the determinants that would
further be included in a multivariate regression model. Vari-
ables with a p-value of <0.15 in the univariate analysis
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Table 1 Baseline characteristics
CIRCULATION CELLS study
population, treatment-naive pa-
tients
(N = 279)
Syntax score (median, IQR) 11 (4, 18)
Male (n, %) 188 (67.4%)
Age in years (mean, SD) 60.9 ± 10.4
Race (n, %)
Caucasian 266 (95.3%)
Hindu 1 (0.4%)
Asian 9 (3.2%)
Other 3 (1.1%)
Hypertension (n, %) 162 (58.1%)
Diabetes mellitus (n, %) 54 (19.4%)
Dyslipidaemia (n, %) 164 (58.8%)
Smoking habits (n, %)
Active Smokers 59 (21.1%)
Ex-smokers 29 (10.4%)
Never smokers 190 (68.1%)
Familiar history premature
CVD (n, %)
133 (47.7%)
BMI (mean, SD) kg/m2 27.2 ± 4.1
PVD (n, %) 29 (10.4%)
Renal insufficiency (n, %) 3 (1.1%)
CVA/TIA (n, %) 20 (7.2%)
Previous MI (n, %) 40 (14.3%)
LVEF (n, %)
>50% 99 (35.5%)
30–50% 17 (6.1%)
<30% 2 (0.7%)
Unknown/missing data 182 (65.3%)
Salicylates 216 (77%)
Clopidogrel 109 (39%)
ACE inhibitors 77 (28%)
ARB 45 (16%)
Statines 198 (71%)
Beta-adrenergic blocking
agent
187 (67%)
Calcium antagonists 56 (20%)
Nitrates 83 (30%)
BMI body mass index, CVD cardiovascular disease, PVD peripheral
vascular disease, CVA/TIA cerebrovascular accident/transient
ischaemic attack, MI myocardial infarction, ACE angiotensin
converting enzyme, ARB angiotensin receptor blockers, LVEF left
ventricular ejection fraction, IQR interquartile range, SD standard
deviation
were considered eligible. An additional univariate analysis
was performed, adjusting the determinants for age and sex
which are considered non-modifiable biological factors. In
the multivariate model, a p-value of <0.05 was considered
significant. Statistical analysis was performed with SPSS
(SPSS v.22, Chicago, IL).
Table 2 Clinical syndrome and syntax score based on presentation
Clinical Syndrome N (%) Syntax score (me-
dian, IQR)
Stable angina 209 (74.9%) 11 (5, 19)
Unstable angina 15 (5.4%) 15 (7, 18)
NSTEMI 36 (12.9%) 16 (9, 24.5)
Atypical thoracic
pain/non-significant CAD
19 (6.8%) 0 (0, 0)
NSTEMI non-ST-segment elevation myocardial infarction,
CAD coronary artery disease, IQR interquartile range
Results
Two hundred and seventy-nine patients were included
(mean age 60.9 ± 10.4 years). The prevalence of classical
risk determinants for CAD and baseline characteristics are
presented in Table 1.
The clinical setting of presentation and the calculated
SS per group are provided in Table 2. The majority of the
patients presented with stable angina (209 patients, 74.9%),
whereas 15 (5.9%) presented with unstable angina and 36
(12.9%) with NSTEMI; there were 19 patients included
in the study where, despite the complaints, no significant
CAD was identified (and therefore the SS was given as
zero). Despite the fact that this study included coronary
intervention-naive patients, the vast majority was already
using antiplatelet agents and statins at inclusion. The latter
is reflected in the lipid profile and the relatively low LDL
cholesterol values presented in Fig. 1.
The calculated SS of the total population had a median
value of 11 (IQR: 4, 18). The majority of the patients (n =
236) had a calculated low SS (LSS, <23), 30 patients had
a medium SS (MSS, 23–32) while 13 were found with
a high SS (HSS, >32). The median values and interquartile
range (IQR) of each group are presented in Fig. 2.
The results of the univariate and multivariate analysis are
presented in Tables 3 and 4. Age was clearly associated with
a higher SS, while male sex did not reach statistical signif-
icance. After adjustment for the non-modifiable biological
factors (age and sex), diabetes mellitus, smoking, renal in-
sufficiency, body mass index and a history of CVD and
myocardial infarction are all positively and strongly associ-
ated with a higher SS. In the multivariate analysis following
a general linear model, age and male sex were identified as
significant independent risk factors (age: regression coeffi-
cient 0.185, p = 0.007, male: 3.488, p = 0.012); the associa-
tion of other determinants with SS is eliminated except for
renal insufficiency and smoking (renal failure, regression
coefficient: 13.737, p = 0.029, smoking regression coeffi-
cient: 3.889, p = 0.009).
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Fig. 1 Lipid profile of in-
cluded patients at inclusion.
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Fig. 2 Distribution of Syntax
scores in the included popula-
tion. (LSSG low syntax score
group, MSSG medium syntax
score group, HSSG high syn-
tax score group, SD standard
deviation)
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Discussion
Our analysis examines the relationship of SS with tradi-
tional cardiovascular risk factors in a selected population
of patients undergoing coronary angiography from the CIR-
CULATING CELLS study. We demonstrate a positive cor-
relation with increased age, as well as the presence of di-
abetes mellitus, smoking habit and obesity. A positive cor-
relation is also demonstrated with renal insufficiency and,
as expected, with previously established CAD (in the form
of previous myocardial infarction). In the multivariate anal-
ysis model, age, male sex, history of smoking and renal
insufficiency remained as predictors of an increased SS.
An accessible and reproducible method to evaluate the
angiographic extension of CAD is mandatory for further
analysis associating potential biomarkers and coronary
atherosclerosis severity. SS has become an indispensable
tool to evaluate CAD complexity and to guide the revas-
cularisation approach election [2, 6]. Recently, it has been
demonstrated that the SYNTAX score II guides the revas-
cularisation strategy choice better by combining SS with
a number of clinical variables [7]. For the purpose of
our study, SS was chosen due to its strict anatomical-
based design to assess CAD complexity. Current coro-
nary revascularisation guidelines advocate the use of SS
to determine the revascularisation modality [8, 9], despite
its limitations [10] and despite the fact that criticism is
being raised whether the conclusions of the SYNTAX trial
still apply in current clinical practice with the use of 2nd
and 3rd generation drug-eluting stents [11]. SS has also
been used as a surrogate marker of CAD extent in studies
which sought to establish correlations of several clinical
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Table 3 Univariate and sex/age corrected analysis of risk factors, as determinants of SYNTAX score
Univariate re-
gression coeffi-
cient (beta’s)
95% CI p-value Regression coef-
ficient adjusted
for age and sex
95% CI p-value
Age 0.140 0.019, 0.261 0.024 – – –
Male sex 2.569 –0.148, 5.287 0.064 – – –
Diabetes mellitus 3.745 0.530, 6.960 0.023 3.285 0.083, 6.487 0.044
Hypertension 2.521 –0.060, 5.102 0.056 2.380 –0.233, 4.992 0.074
Dyslipidaemia 1.877 –0.719, 4.4.72 0.156 2.049 –0.517, 4.615 0.117
Renal insufficiency 17.467 5.209, 29.726 0.005 16.664 4.398, 28.930 0.008
History of
CVA/TIA
4.341 –0.603, 9.284 0.085 4.356 –0.544, 9.256 0.081
Previous MI 4.558 0.940, 8.177 0.014 4.344 0.768, 7.920 0.017
Smokinga 2.144 –0.610, 4.898 0.127 3.884 1.010, 6.759 0.008
BMI 0.394 0.076, 0.712 0.015 0.422 0.108, 0.736 0.009
CVA/TIA cerebrovascular accident/transient ischemic attack, MI myocardial infarction, BMI body mass index, CI confidence interval
aEver smokers/current smokers versus never smokers
Table 4 Multivariate model
analysis of risk factors as deter-
minants of SYNTAX score
Regression coefficient
(betas)
95% CI p-value
Age 0.186 0.053, 0.320 0.006
Male sex 3.454 0.754, 6.155 0.012
Diabetes mellitus 1.902 –1.529, 5.332 0.276
Hypertension 1.280 –1.463, 4.022 0.359
Dysplipidaemia 1.249 –1.437, 3.935 0.361
Renal insufficiency 13.737 1.397, 26.077 0.029
History of CVA/TIA 4.022 –1.213, 9.257 0.132
Previous MI 2.921 –0.709, 6.551 0.114
Smokinga 3.889 0.984, 6.794 0.009
BMI 0.223 –0.111, 0.557 0.189
CVA/TIA cerebrovascular accident/transient ischemic attack, MI myocardial infarction, BMI body mass in-
dex, CI confidence interval
aEver smokers/current smokers versus never smokers
and biochemical variables with coronary atherosclerosis [5,
12, 13]. However, SS in this context has not been properly
validated.
The role of age, male gender, smoking, diabetes melli-
tus and obesity as determinants of CAD has been discussed
extensively since the publication of the Framingham Heart
study and a series of landmark studies indicating a causal re-
lationship with atherosclerosis [14, 15]. Our study suggests
a positive association of these parameters with the complex-
ity of CAD, as expressed through SS. Aging is associated
with progressive endothelial dysfunction, occurring earlier
in males, presumably due to the protective role of oestro-
gens in pre-menopausal women [16]. Smoking affects all
phases of atherosclerosis, from endothelial dysfunction to
acute clinical events [17]. In diabetes hyperglycaemia, in-
sulin resistance and free fatty acid release have been shown
to lead to increased oxidative stress and therefore accelerate
atherosclerosis [18]. Diabetes was not however a predictor
of SS in the multivariate analysis in our study. Although
this could be explained by the relatively small sample size,
it should be noticed that only coronary lesions located in
vessels with diameters >1.5 mm qualify for SS calculation.
Therefore, CAD extension in diabetic patients might be un-
derestimated with this method.
The role of BMI as predictor of CAD is controversial.
In a study evaluating 13,874 patients referred for computed
tomographic angiography, an increased BMI was associ-
ated to a higher prevalence, extension and severity of CAD
and increased risk of myocardial infarction [19]. BMI was
also a predictor of CAD but not of its severity in another
similar study including 1706 patients [20]. On the other
hand, an inverse relationship of obesity with death in pa-
tients with known cardiovascular disease is well known and
described as the ‘obesity paradox’ [21, 22]. These findings
may be related to several factors, as the inability of BMI
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to discriminate between excessive amounts of body fat and
increments of lean mass or the introduction of more ag-
gressive secondary prevention strategies in patients with
high BMI. Based on our results, BMI might not be reliable
as a clinical marker of complex CAD. Other parameters
focused on body fat distribution, such as the presence of
central obesity, waist circumference or waist-to-hip ratio,
have been related to higher rates of myocardial infarction
or even mortality. Further analysis is required to determine
their association with SS.
Although the number of patients with renal insufficiency
in our study is limited and prevents us from drawing defini-
tive conclusions, our findings are in accordance with a pre-
vious study comprising 2262 patient who underwent coro-
nary angiography, where kidney function was found to be
an independent predictor of SS [23].
The lack of correlation with other well-known vascular
risk factors, such as dyslipidaemia or hypertension, most
likely reflects the impact of prevention strategies in this
population. A high number of patients undergoing CAG
are treated with statins in current practice. Statins reduce
the concentration of circulating LDL cholesterol and other
apo-B-containing lipoproteins, reduce moderately elevated
triglycerides levels and elevate HDL cholesterol levels up
to 5–10%. Besides, they have been proven to reduce plaque
burden and induce plaque stabilisation [24]. Angiotensin-II
receptor blocking agents, broadly used in patients at high
vascular risk, are linked to lower rate of coronary atheroma
progression [25]. Statins were used by 71% of the individu-
als of our cohort, angiotensin converting enzyme inhibitors
by 28% and angiotensin receptor blockers by 16% at inclu-
sion. Therefore, the association of potentially modifiable
risk factors, such as hypertension and dyslipidaemia, and
extension or complexity of CAD may have become spuri-
ous.
As mentioned above, SS has been used as a surrogate
marker of CAD and has been compared with several bio-
logical variables potentially implicated in the development
of coronary atherosclerosis as fasting blood glucose, mono-
cyte subtypes, red cell distribution width or bilirubin levels
[26–28]. We believe that the demonstrated association of
‘non-modifiable’ risk factors with the complexity of CAD
legitimates the use of SS in this scenario.
Limitations
Although this is a prospective study, the study cohort was
selected among patients included in the CIRCULATING
CELLS trial following specific inclusion criteria. Thus, pa-
tients with STEMI, previous bypass or previous coronary
interventions were excluded. Since these patients theoreti-
cally have more extended CAD, their exclusion may con-
dition a selection bias. The relatively small sample size
and the limited number of the analysed baseline conditions
might have an influence in the observed results.
SS limitations should be addressed. Only coronary steno-
sis ≥50% in vessels with a diameter ≥1.5 mm qualify for
scoring. Lumen reductions below 50% are therefore ex-
cluded. Hence, a patient with a focal 70% stenosis in the
proximal circumflex artery with no other lesions will have
a higher SS than a patient with 40% lesions in multiple seg-
ments. This illustrates that higher SS values do not neces-
sarily imply more extended atherosclerosis. SS calculation
relies exclusively on a visual evaluation of the coronary an-
giography, implying potential misinterpretation and inter-
observer variability [10, 29].
Conclusion
In a selected cohort of revascularisation-naive patients with
CAD undergoing coronary angiography, non-modifiable
cardiovascular risk factors such as advanced age, male
sex, as well as smoking and renal failure, were indepen-
dently associated with CAD complexity assessed by SS.
SS may be a valid marker of CAD extension to establish
relationships with potential novel biomarkers of coronary
atherosclerosis.
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